Pharm D (University of Mali) by background, prof Halidou Tinto obtained his Post Graduate Diploma in Biology in 1998 at the University of Ouagadougou, Burkina Faso. From 1995 to 1999, he worked as research Associate at Centre Muraz, Burkina Faso where he has been involved in the epidemiological surveillance of malaria drug resistance. From 1999 to 2000, he worked at the Royal Danish School of Pharmacy, Denmark as Research fellow in the Development of alternative medicine against malaria. From 2001, he was recruited as research associate at the Institute for Health Sciences Research (IRSS) in Burkina Faso. From 2003 to 2006, he worked as PhD fellow in Medical Sciences at the Institute of Tropical Medicine (ITM) in Antwerp, Belgium, where he studied the epidemiology of malaria drug resistance in Burkina Faso and the mechanism of the resistance in Rwanda. After obtaining his PhD in 2006, he went back in Burkina Faso, where he created in 2009 the Clinical Research Unit of Nanoro (CRUN). The latter provides today a well-equipped GCP-compliant clinical research platform for testing new interventions (drugs, vaccines, diagnostics, etc). Within the last 10 years the CRUN conducted in collaboration with several academic institutions and pharmaceuticals companies (GSK, Sanofi, Novartis, Sigma Tau, Shin Poong Pharmaceuticals, Janssen, etc) over twenty phase 2, 3 and 4 clinical trials at ICH/GCP standards including the GSK phase 3 malaria vaccine trial (RTS,S). Prof Tinto has been appointed as Scientific Director of Centre Muraz from 2013 to 2014 and since 2017 as Regional Director of IRSS in Nanoro in the Centre-West Region of Burkina Faso. He has been graduated in July 2016 as Director of Research in Parasitology and is currently acting as Professor associated at the Nazi Boni University of Bobo-Dioulasso, Burkina Faso. He is author and co-author of 181 publications in international per-reviewed journals.